AI주식인사이트AI Stock Insight
C

셀리드

299660KOSDAQ

54.0 / 100

Reference Date: 2026-10-23

Financial Score21.5 / 40
News Sentiment12.5 / 25
Momentum6.0 / 20
Disclosure14.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly down 2.7% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

Cellid is a biopharmaceutical company with proprietary technologies CeliVax (cancer immunotherapy vaccine) and Ad5/35 (infectious disease prevention vaccine), developing six cancer immunotherapy vaccines including BVAC-C and BVAC-E6E7, as well as a COVID-19 vaccine. It is currently conducting Phase 1/2a and 3 clinical trials, and generates revenue through CMO/CDMO services and e-commerce sales, though no products are currently on the market.

Number of Employees

49people

Average Salary

49.7M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
0.86Industry Average 1.205.5Point

Lower than industry avg (good)

ROE
-19.25Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
9.75Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20254.0 / 10 points
Revenue Growth Rate
3.0 / 3

Avg ▲112.3% (1-year basis)

Operating Profit Growth Rate
1.0 / 3

Avg ▲3.6% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -27.6% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (36%)

Current 2,165Won52-week high 4,11052-week low 1,025
1-month return2.0Point

1m -2.70% (slight drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

19 totalPositive 2Neutral 17Negative 0
  • Neutral의결권대리행사권유참고서류2026-10-21
  • Neutral[기재정정]주주총회소집결의 (임시주주총회)2026-10-21
  • Neutral주주총회소집공고2026-10-21
  • Neutral[기재정정]주식매수선택권부여에관한신고2026-10-19
  • Neutral[기재정정]주식매수선택권부여에관한신고2026-10-19